首页 > 最新文献

Medicom Conference Report ASCO GI 2023最新文献

英文 中文
SWOG 1815, first-ever phase 3 trial in BTC, fails 首个BTC三期临床试验SWOG 1815失败
Pub Date : 2023-03-17 DOI: 10.55788/a8a89b60
Robert van den Heuvel
{"title":"SWOG 1815, first-ever phase 3 trial in BTC, fails","authors":"Robert van den Heuvel","doi":"10.55788/a8a89b60","DOIUrl":"https://doi.org/10.55788/a8a89b60","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130361617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy or not in locally advanced oesophageal or junctional cancer? 局部晚期食管癌或结癌是否需要放疗?
Pub Date : 2023-03-17 DOI: 10.55788/b0f7c6f2
Robert van den Heuvel
{"title":"Radiotherapy or not in locally advanced oesophageal or junctional cancer?","authors":"Robert van den Heuvel","doi":"10.55788/b0f7c6f2","DOIUrl":"https://doi.org/10.55788/b0f7c6f2","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133403723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer Zolbetuximab联合mFOLFOX6治疗胃癌cldn18.2阳性亚组成功
Pub Date : 2023-03-17 DOI: 10.55788/f811f2b0
Robert van den Heuvel
{"title":"Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer","authors":"Robert van den Heuvel","doi":"10.55788/f811f2b0","DOIUrl":"https://doi.org/10.55788/f811f2b0","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115980321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3-year follow-up data confirms benefits of nivolumab plus chemotherapy 3年随访数据证实了纳武单抗联合化疗的益处
Pub Date : 2023-03-17 DOI: 10.55788/68722540
Robert van den Heuvel
{"title":"3-year follow-up data confirms benefits of nivolumab plus chemotherapy","authors":"Robert van den Heuvel","doi":"10.55788/68722540","DOIUrl":"https://doi.org/10.55788/68722540","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131187655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality-of-life benefits for tislelizumab in uHCC tislelizumab治疗uHCC的生活质量获益
Pub Date : 2023-03-17 DOI: 10.55788/af968169
Robert van den Heuvel
{"title":"Quality-of-life benefits for tislelizumab in uHCC","authors":"Robert van den Heuvel","doi":"10.55788/af968169","DOIUrl":"https://doi.org/10.55788/af968169","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125218823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer? S-1辅助化疗:2期胃癌4个疗程还是8个疗程?
Pub Date : 2023-03-17 DOI: 10.55788/318bec28
Robert van den Heuvel
{"title":"S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?","authors":"Robert van den Heuvel","doi":"10.55788/318bec28","DOIUrl":"https://doi.org/10.55788/318bec28","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130829478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC 纳武拉特治疗BTC的安全性可接受,疗效令人鼓舞
Pub Date : 2023-03-17 DOI: 10.55788/f6cff4ed
Robert van den Heuvel
{"title":"Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC","authors":"Robert van den Heuvel","doi":"10.55788/f6cff4ed","DOIUrl":"https://doi.org/10.55788/f6cff4ed","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126527026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT ctDNA在监测肛癌患者接受CRT时似乎是有用的
Pub Date : 2023-03-17 DOI: 10.55788/caf1e327
Robert van den Heuvel
{"title":"ctDNA appears useful in monitoring patients with anal cancer undergoing CRT","authors":"Robert van den Heuvel","doi":"10.55788/caf1e327","DOIUrl":"https://doi.org/10.55788/caf1e327","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122511172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival following postoperative sorafenib plus TACE in HCC 肝癌患者索拉非尼联合TACE术后生存率提高
Pub Date : 2023-03-17 DOI: 10.55788/30fb3fda
Robert van den Heuvel
{"title":"Improved survival following postoperative sorafenib plus TACE in HCC","authors":"Robert van den Heuvel","doi":"10.55788/30fb3fda","DOIUrl":"https://doi.org/10.55788/30fb3fda","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122738352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer LATG/LAPG在1期胃癌中表现出良好的长期疗效
Pub Date : 2023-03-17 DOI: 10.55788/4d83db52
Robert van den Heuvel
{"title":"LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer","authors":"Robert van den Heuvel","doi":"10.55788/4d83db52","DOIUrl":"https://doi.org/10.55788/4d83db52","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"144 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133896364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicom Conference Report ASCO GI 2023
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1